Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-04-06
2009-06-23
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S080000
Reexamination Certificate
active
07550501
ABSTRACT:
The present invention relates to compounds and methods useful in the prevention or treatment of diseases or conditions associated with Toll-like receptor 2 activation.
REFERENCES:
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6835721 (2004-12-01), Hawkins et al.
patent: 7202234 (2007-04-01), Chow et al.
patent: 1 147 117 (2004-06-01), None
patent: WO 98/50547 (1998-11-01), None
patent: WO 03/020760 (2003-03-01), None
Hoffman et al. Nature Reviews Drug Discovery, 2005, 4, 879-880.
International Search Report and Written Opinion from International Application No. PCT/US04/35447 dated Feb. 7, 2005 and mailed Jun. 7, 2005.
Mel'nik et al., “Complex Lipids,” Zhurnal Obshchei Khimi 37:2452-2455, 1967.
Yang et al. “Toll-like Receptor-2 Mediates Lipopolysaccharide-Induced Cellular Signaling,” Nature 395(6699):284-288, 1998.
Rock et al., “A Family of Human Receptors Structurally Related to Drosophila Toll,”Proc Natl Acad Sci USA. 95(2): 588-93, 1998.
Schwandner et al., “Peptidoglycan- and Lipoteichoic Acid-Induced Cell Activation is Mediated by Toll-Like Receptor 2,”J Biol Chem.274 (25): 17406-9, 1999.
Yoshimura et al., “Cutting Edge : Recognition of Gram-Positive Bacterial Cell Wall Components by the Innate Immune System Occurs via Toll-Like Receptor 2,”Immunol.163(1): 1-5, 1999.
Aliprantis et al., “Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-Like Receptor-2”,Science285(5428): 736-9, 1999.
Brightbill et al., “Host Defense Mechanisms Triggered by Microbial Lipoproteins Through Toll-Like Receptors,” 285(5428): 732-6, 1999.
Tekeuchi et al., “Differential Roles of TLR2 and TLR4 in Recognition of Gram-Negative and Gram-Positive Bacterial Cell Wall Components,”Immunity11(4): 443-51, 1999.
Underhill et al., “The Toll-Like Receptor 2 is Recruited to Macrophage Phagosomes and Discriminates Between Pathogens,”Nature401(6755):811-5, 1999.
Lien et al., “Toll-Like Receptor 2 Functions as a Pattern Recognition Receptor for Diverse Bacterial Products,”J Biol Chem.274(47): 33419-25, 1999.
Kim et al., “Activation of Toll-Like Receptor 2 in Acne Triggers Inflammatory Cytokine Responses,”J Immunol.169(3): 1535-41, 2002.
Asai et al., “Bacterial Fimbriae and Their Peptides Activate Human Gingival Epithelial Cells Through Toll-Like Receptor 2,”Infect Immun.69(12): 7387-95, 2001.
Zuany-Amorim et al., “Toll-Like Receptors as Potential Therapeutic Targets for Multiple Diseases,”Nat Rev Drug Discov.1(10):797-807, 2002.
Flo et al. “Human Toll-Like Receptor 2 Mediated Monocyte Activation byListeria monocytogenes, but Not by Group B Streptococci or Lipopolysaccharide,”J Immunol.164(4):2064-9, 2000.
Decker, “Sepsis: Avoiding Its Deadly Toll,”J Clin Invest.113(10):1473-81, 2004.
Spyvee et al., “Toll-Like Receptor 2 Antagonists. Part 1: Preliminary SAR Investigation of Novel Synthetic Phospholipids,”Bioorg Med Chem Lett.15(24):5494-8. 2005.
Bsibsi et al., “Broad Expression of Toll-Like Receptors in the Human Central Nervous System,”J Neuropathol Exp Neurol.61(11): 1013-21. 2002.
Marshak-Rothstein, “Toll-Like Receptors in Systemic Autoimmune Disease,”Nat Rev Immunol.6(11):823-35, 2006.
Ingalls et al., “Differential Roles of the TLR2 and TLR4 in the Host Response to Gram-Negative Bacteria: Lessons from a Lipopolysaccharide-Deficient Mutant of Neisseria Meningitidis,”J Endotoxin Res.6(5):411-5, 2000.
Kang et al., “Detection of Toll-Like Receptor 2 (TLR2) Mutation in the lepromatous Leprosy Patients,”FEMS Immunol Med Microbiol.31(1): 53-8, 2001.
Baker et al., “Normal Keratinocytes express Toll-Like Receptors (TLRs) 1, 2 and 5: Modulation of TLR Expression in Chronic Plaque Psoriasis,”Br J Dermatol.148(4): 670-9, 2003.
Wetzler, “The Role of Toll-Like Receptor 2 in Microbial Disease and Immunity,”Vaccine.1;21 Suppl 2:S55-60, 2003.
McNamara et al., “Signaling Networks Controlling Mucin Production in Response to Gram-Positive and Gram-Negative Bacteria,”Glycoconi J.8(9):715-22, 2001.
Meng et al., “Antagonistic Antibody Prevents Toll-Like Receptor 2-Driven Lethal Shock-Like Syndromes,”J Clin Invest.113(10):1387-9, 2004.
Asea et al., “Novel Signal Transduction Pathway Utilized by Extracellular HSP70: Role of Toll-Like Receptor (TLR) 2 and TLR4,”J Biol Chem.277(17):15028-34, 2002.
Sobek et al., “Direct Toll-Like Receptor 2 Mediated Co-Stilmulation of T Cells in the Mouse System as a Basis for Chronic Inflammatory Joint Disease,”Arthritis Res Ther.6(5):R433-46, 2004.
Marshall et al., “Toll-Like Receptor-Mediated Activation of Mast Cells: Implications for Allergic Disease?,”Int Arch Allergy Immunol.132(2):87-97, 2003.
Seya et al., “A Lipoprotein Family fromMycoplasma fermentansConfers Host Immune Activation Through Toll-Like Receptor 2,”Int J Biochem Cell Biol.34(8): 901-6, 2002.
Fusunyan et al., “Evidence for an Innate Immune Response in the Immature Human Intestine: Toll-Like Receptors on Fetal Enterocytes,”Pediatr Res.49(4): 589-93, 2001.
Murray et al., “Lipopolysaccharide from the Periodontal pathogenPorphyromonas gingivalisPrevents Apoptosis of HL60-Derived Neutrophils In Vitro,”Infect Immun.71(12): 7232-5, 2003.
Wedzicha, “Exacerbations: Etiology and Pathophysiologic Mechanisms,”Chest.121(5 Suppl):136S-141S, 2002.
Pålsson-McDermott et al., “The Potential of Targeting Toll-Like Receptor 2 in Autoimmune and Inflammatory Diseases,”Ir J Med Sci.176(4):253-60, 2007.
Edfeldt et al., “Expression of Toll-Like Receptors in Human Atherosclerotic Lesions: A Possible Pathway for Plaque Activation,”Circulation.105(10): 1158-61, 2002.
McInturff et al., “The Role of Toll-Like Receptors in the Pathogenesis and Treatment of Dermatological Disease,”J Invest Dermatol.125(1):1-8, 2005.
Chow Jesse
Gusovksy Fabian
Hawkins Lynn
Spyvee Mark
Anderson Rebecca L
Clark & Elbing LLP
Eisai R&D Management Co., Ltd.
Nolan Jason
LandOfFree
Compounds and methods for treating toll-like receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds and methods for treating toll-like receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and methods for treating toll-like receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4148632